10:09:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning DIGN 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-12 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning DIGN 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning DIGN 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning DIGN 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2021-01-11 Extra Bolagsstämma 2021
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-26 Ordinarie utdelning DIGN 0.00 SEK
2020-06-25 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2020-02-10 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning DIGN 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-15 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-11-27 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-22 Kvartalsrapport 2018-Q1
2018-04-27 Ordinarie utdelning DIGN 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-02 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-25 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning DIGN 0.00 SEK
2016-03-22 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-05-19 Ordinarie utdelning DIGN 0.00 SEK
2015-02-24 Bokslutskommuniké 2014
2014-11-25 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-20 Kvartalsrapport 2014-Q1
2014-05-19 Ordinarie utdelning DIGN 0.00 SEK
2014-05-16 Årsstämma 2014
2014-03-04 Extra Bolagsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-08-28 Extra Bolagsstämma 2013
2013-05-22 Kvartalsrapport 2013-Q1
2013-05-22 Ordinarie utdelning DIGN 0.00 SEK
2013-05-21 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-11-28 Kvartalsrapport 2012-Q3
2012-10-30 Extra Bolagsstämma 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-29 Årsstämma 2012
2012-05-28 Kvartalsrapport 2012-Q1
2012-02-27 Bokslutskommuniké 2011
2011-11-17 Kvartalsrapport 2011-Q3
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-13 Ordinarie utdelning DIGN 0.00 SEK
2011-06-10 Årsstämma 2011
2011-05-30 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-11-18 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-21 Ordinarie utdelning DIGN 0.00 SEK
2010-05-18 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2023-08-17 14:12:37

A long-term study of The DigniCap® Scalp Cooling System was presented by Dr. Hope Rugo at the Multinational Association of Supportive Care in Cancer Annual Meeting in June and has now been published in the journal  Supportive Care in Cancer (https://pubmed.ncbi.nlm.nih.gov/37341793/). With a five-year follow-up period, this is the first long term study of scalp cooling to be published.

"Patient safety is critical in the administration of scalp cooling, and we are pleased that this final phase of our pivotal trial has now been published to clearly demonstrate the safety of this therapy and to reiterate the efficacy of DigniCap shown in the pivotal trial," said Catarina Löwenadler, CEO of Dignitana.  

 "In the pivotal trial 66.3 percent of patients using DigniCap kept the majority of their hair using the Dean scale. We are now seeing even better results with our next generation DigniCap Delta device, with 75 percent of patients reporting a high degree of satisfaction on the same scale. Additionally, 94 percent of DigniCap patients surveyed state they would recommend DigniCap to others, and that level of endorsement is a significant accomplishment for any business," she said.

The DigniCap Long Term Safety study followed patients for five years to evaluate risk of metastases and concluded that:
  • Scalp cooling using DigniCap in patients with early-stage breast cancer receiving taxane based neo/adjuvant chemotherapy is safe and effective.
  • Recurrences occurred in a small number of patients as expected.
  • No scalp metastases were observed. There is no evidence that scalp cooling increases the risk of scalp metastases.

The study poster may be viewed here: Long-term Safety Follow-Up of Patients with Early Stage Breast Cancer (https://dignicap.com/wp-content/uploads/2023/08/2023-DigniCap-Long-Term-Safety-Abstract-poster_Rugo-MASCC.pdf)

DigniCap is used to minimize chemotherapy induced hair loss in patients with solid tumor cancers. In 2015 the initial phase of this study led to DigniCap becoming the first scalp cooling device to receive FDA clearance, thereby introducing safe and effective scalp cooling to the United States. This pivotal trial achieved clinically superior results, with the majority of patients keeping at least 50 percent of their hair while undergoing chemotherapy.

The pivotal trial was led by Dr. Hope Rugo at UCSF with five pivotal trial sites: University of California San Francisco Comprehensive Cancer Center, San Francisco; Icahn School of Medicine at Mount Sinai, New York; University of California Los Angeles; and Weill Cornell Medical College, New York.